Differential transcriptomic profiling in ibrutinib-naïve versus ibrutinib-resistant Richter syndrome
- PMID: 34806797
- DOI: 10.1002/hon.2950
Differential transcriptomic profiling in ibrutinib-naïve versus ibrutinib-resistant Richter syndrome
Comment on
-
Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia.Blood. 2021 May 20;137(20):2800-2816. doi: 10.1182/blood.2020005650. Blood. 2021. PMID: 33206936 Free PMC article. Clinical Trial.
References
REFERENCES
-
- Wang Y, Ding W. Richter transformation of chronic lymphocytic leukemia in the era of novel agents. Clin Adv Hematol Oncol. 2020;18(6):348-357.
-
- Herishanu Y, Pérez-Galán P, Liu D, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011;117(2):563-574.
-
- Ayers M, Lunceford J, Nebozhyn M, et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Investig. 2017;127(8):2930-2940.
-
- Bhattacharya A, Hamilton AM, Furberg H, et al. An approach for normalization and quality control for NanoString RNA expression data. Brief Bioinform. 2021;22(3). https://doi.org/10.1093/bib/bbaa163.
-
- Klintman J, Appleby N, Stamatopoulos B, et al. Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia. Blood. 2021;137(20):2800-2816.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources